Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Simplify your finances with user-friendly finance management tools. These resources will help you stay organized and in control of your money.
22,433 articlesBiotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Applied Optoelectronics leads a broad optics rally, jumping 24% as AI-driven data-center capex fuels demand for high-...
Today’s stock market today managed a small advance even as oil prices rose and geopolitical headlines persisted. This...
Palantir remains a topic of debate as dividend-focused peers outperform in choppy markets. Here’s how the latest move...
As defense demand accelerates, Anduril Industries partnering with Rocket Lab to tackle hypersonics could reshape fund...
A longtime i’m berkshire hathaway investor shifts view on Greg Abel, arguing his disciplined capital allocation and r...
Teva is shifting from a debt-laden generic player to a branded-focused pharma with a stronger balance sheet. This piv...
Nvidia CEO Jensen Huang describes a 1,000% surge in AI compute for agentic AI, triggering a broad rethink of data cen...
As BioHarvest gears up for its Q1 2026 earnings, investors seek clarity on revenue momentum, margins, and the path to...
As SpaceX eyes the public markets, investors buzz about a potential IPO rush and a comeback for stock-split enthusias...
A $50,000 retirement target split 50/50 between REIT dividends and stock dividends changes the math. Today, investors...
HYPE breaks above $57 as a short squeeze pushes the token within 2% of its all-time high, with negative funding and s...